Prognostic parameters established by multivariate analysis including WHO 2007 grading and IDH1-R132H mutation status
| Multivariate Analysis Including 2007 WHO Grading . | ||
|---|---|---|
| Prognostic Parameters . | P-value . | OR (95% CI) . |
| WHO grading | <0.001 | II vs IV: 0.05 (0.02–0.1) III vs IV: 0.17 (0.09–0.32) |
| Surgical approach | <0.001 | Resect. vs BIO: 0.20 (0.12–0.34) |
| Tumor crossing midline | 0.001 | 3.47 (1.78–6.75) |
| Parietal tumor localization | 0.029 | 2.95 (1.62–5.36) |
| METT/N ratio | 0.031 | 1.57 (1.34–1.84) |
| Histology | 0.041 | OT vs AC: 0.24 (0.13–0.45) |
| Multivariate Analysis with Respect to IDH1-R132H Mutation Status | ||
| Prognostic Parameters | P-value | OR (95% CI) |
| Surgical approach | <0.001 | Resect. vs BIO: 0.20 (0.12–0.34) |
| METT/N ratio | 0.001 | 1.57 (1.34–1.84) |
| Tumor crossing midline | 0.001 | 3.47 (1.78–6.75) |
| IDH1-R132H mutation status | 0.001 | 0.26 (0.14–0.49) |
| Therapy following surgery | 0.001 | Surgery vs RCHT: 0.17 (0.08–0.39) RT vs RCHT: 0.14 (0.04–0.54) CHT vs RCHT: not significant |
| Parietal tumor localization | 0.052 | 2.95 (1.62–5.36) |
| Multivariate Analysis Including 2007 WHO Grading . | ||
|---|---|---|
| Prognostic Parameters . | P-value . | OR (95% CI) . |
| WHO grading | <0.001 | II vs IV: 0.05 (0.02–0.1) III vs IV: 0.17 (0.09–0.32) |
| Surgical approach | <0.001 | Resect. vs BIO: 0.20 (0.12–0.34) |
| Tumor crossing midline | 0.001 | 3.47 (1.78–6.75) |
| Parietal tumor localization | 0.029 | 2.95 (1.62–5.36) |
| METT/N ratio | 0.031 | 1.57 (1.34–1.84) |
| Histology | 0.041 | OT vs AC: 0.24 (0.13–0.45) |
| Multivariate Analysis with Respect to IDH1-R132H Mutation Status | ||
| Prognostic Parameters | P-value | OR (95% CI) |
| Surgical approach | <0.001 | Resect. vs BIO: 0.20 (0.12–0.34) |
| METT/N ratio | 0.001 | 1.57 (1.34–1.84) |
| Tumor crossing midline | 0.001 | 3.47 (1.78–6.75) |
| IDH1-R132H mutation status | 0.001 | 0.26 (0.14–0.49) |
| Therapy following surgery | 0.001 | Surgery vs RCHT: 0.17 (0.08–0.39) RT vs RCHT: 0.14 (0.04–0.54) CHT vs RCHT: not significant |
| Parietal tumor localization | 0.052 | 2.95 (1.62–5.36) |
Abbreviations: Resect. = tumor resection, BIO = biopsy, OT = oligodendroglial tumors (oligodendrogliomas and oligoastrocytomas), AC = astrocytomas including glioblastomas, RCHT = radiochemotherapy.
Prognostic parameters established by multivariate analysis including WHO 2007 grading and IDH1-R132H mutation status
| Multivariate Analysis Including 2007 WHO Grading . | ||
|---|---|---|
| Prognostic Parameters . | P-value . | OR (95% CI) . |
| WHO grading | <0.001 | II vs IV: 0.05 (0.02–0.1) III vs IV: 0.17 (0.09–0.32) |
| Surgical approach | <0.001 | Resect. vs BIO: 0.20 (0.12–0.34) |
| Tumor crossing midline | 0.001 | 3.47 (1.78–6.75) |
| Parietal tumor localization | 0.029 | 2.95 (1.62–5.36) |
| METT/N ratio | 0.031 | 1.57 (1.34–1.84) |
| Histology | 0.041 | OT vs AC: 0.24 (0.13–0.45) |
| Multivariate Analysis with Respect to IDH1-R132H Mutation Status | ||
| Prognostic Parameters | P-value | OR (95% CI) |
| Surgical approach | <0.001 | Resect. vs BIO: 0.20 (0.12–0.34) |
| METT/N ratio | 0.001 | 1.57 (1.34–1.84) |
| Tumor crossing midline | 0.001 | 3.47 (1.78–6.75) |
| IDH1-R132H mutation status | 0.001 | 0.26 (0.14–0.49) |
| Therapy following surgery | 0.001 | Surgery vs RCHT: 0.17 (0.08–0.39) RT vs RCHT: 0.14 (0.04–0.54) CHT vs RCHT: not significant |
| Parietal tumor localization | 0.052 | 2.95 (1.62–5.36) |
| Multivariate Analysis Including 2007 WHO Grading . | ||
|---|---|---|
| Prognostic Parameters . | P-value . | OR (95% CI) . |
| WHO grading | <0.001 | II vs IV: 0.05 (0.02–0.1) III vs IV: 0.17 (0.09–0.32) |
| Surgical approach | <0.001 | Resect. vs BIO: 0.20 (0.12–0.34) |
| Tumor crossing midline | 0.001 | 3.47 (1.78–6.75) |
| Parietal tumor localization | 0.029 | 2.95 (1.62–5.36) |
| METT/N ratio | 0.031 | 1.57 (1.34–1.84) |
| Histology | 0.041 | OT vs AC: 0.24 (0.13–0.45) |
| Multivariate Analysis with Respect to IDH1-R132H Mutation Status | ||
| Prognostic Parameters | P-value | OR (95% CI) |
| Surgical approach | <0.001 | Resect. vs BIO: 0.20 (0.12–0.34) |
| METT/N ratio | 0.001 | 1.57 (1.34–1.84) |
| Tumor crossing midline | 0.001 | 3.47 (1.78–6.75) |
| IDH1-R132H mutation status | 0.001 | 0.26 (0.14–0.49) |
| Therapy following surgery | 0.001 | Surgery vs RCHT: 0.17 (0.08–0.39) RT vs RCHT: 0.14 (0.04–0.54) CHT vs RCHT: not significant |
| Parietal tumor localization | 0.052 | 2.95 (1.62–5.36) |
Abbreviations: Resect. = tumor resection, BIO = biopsy, OT = oligodendroglial tumors (oligodendrogliomas and oligoastrocytomas), AC = astrocytomas including glioblastomas, RCHT = radiochemotherapy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
